Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (2686)	11/2/2001 8:20:15 AM
From: orkrious	Read Replies (3) \| Respond to of 99280

Well, I've extricated myself from my AMAT. Now if someone would just hid my bids on KLAC and NVLS. With ABN's upgrade, I likely can lay them out higher.

To: Zeev Hed who wrote (2686)	11/2/2001 9:31:20 AM
From: manny t	Read Replies (1) \| Respond to of 99280

NOVN, NOVN, 09:23 ET Noven Pharma (NOVN) 22.25: -- Update -- CE Unterberg Towbin maintaining Strong Buy rating despite negative news that international orders from Novartis would be weak in 2H01 and likely impact 2002 as well. Reduced guidance for 2002 reflects lower orders for Estalis in 2001 and a lack of commitment by Novartis' to actively convert prescriptions from Estraderm to Estradot. Firm sees significant value that has been obscured by the current earnings outlook.